Infectious complications in kidney transplant recipients across Africa: a scoping review of epidemiology, microbiology, and prophylaxis strategies
- 1Medical and Scientific Research Center, University of Ghana Medical Center
Abstract
Background Infectious complications remain the leading cause of morbidity and mortality in kidney transplant recipients (KTRs) across Africa, where immunosuppression is delivered amid endemic pathogens, resource constraints, and limited microbiological surveillance. These challenges are compounded by near-universal cytomegalovirus (CMV) seropositivity, high tuberculosis burden, and constrained access to standard prophylactic antivirals. Objectives To synthesize evidence on the epidemiology, microbiology, and management of infectious complications in African KTRs, with emphasis on context-adapted prophylaxis strategies and systemic gaps. Methods This scoping review searched PubMed and African Journals Online (2015–2025) for primary cohort studies, systematic reviews, and clinical trials published between 2015 and 2025 reporting infection outcomes in African KTRs, supplemented by global evidence on CMV prophylaxis in resource-limited settings. Foundational studies predating 2015 were included where no more recent equivalent existed. This review was conducted following the PRISMA Extension for Scoping Reviews (PRISMA-ScR). Studies were eligible if they reported infection outcomes in African kidney transplant recipients. Data were charted descriptively by infection type, country, and prophylaxis strategy. Results Bacterial urinary tract infections predominate early post-transplant, with Escherichia coli causing up to 54% of cases. CMV infection occurs in 13–63% of seropositive recipients despite prophylaxis, with rates varying by regimen and monitoring intensity; tissue-invasive disease is associated with acute rejection rates approaching 50%. Low-dose valacyclovir shows encouraging prophylactic efficacy comparable to valganciclovir at approximately one-sixth the cost, suggesting it may represent a pragmatic alternative in resource-limited African settings where valganciclovir is unavailable or unaffordable. Pediatric transplantation remains severely underdeveloped across sub-Saharan Africa, compounded by weight-based CMV dosing challenges and absent dedicated pediatric units. Critical systemic gaps, nephrology workforce deficits, and near-total absence of transplant infectious disease subspecialty training perpetuate high infectious morbidity after transplantation. Conclusions Improving outcomes will require evaluation of cost-effective prophylaxis protocols through prospective multicenter registries, alongside urgent investment in transplant infectious disease workforce capacity.
Related
- Transition from extended to single-dose antibiotic prophylaxis was not associated with increased postoperative infectious complications in urologic surgery
- How an Infectious Diseases and Clinical Microbiology Clerkship Affects Medical Students' HIV/AIDS Knowledge and Attitudes
- Andes hantavirus outbreak on a cruise ship—an European Society of Clinical Microbiology and Infectious Disease Emerging Infections Subcommittee rapid assessment
- Artificial Intelligence in Infectious Diseases and Clinical Microbiology
- Consensus Guidance for Beta‐Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases PK/PD of Anti‐Infectives Study Group, Infectious Diseases Society of America, International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Society of Critical Care Medicine, and the Society of Infectious Diseases Pharmacists
BibTeX
@article{arthur2026infectious,
title = {{Infectious complications in kidney transplant recipients across Africa: a scoping review of epidemiology, microbiology, and prophylaxis strategies}},
author = {Sabastine Eugene Arthur and AnneMarie Sankofi and Michella Naa Awula Atswei Laryea and Richeal Owusu and James Odame Aboagye and Catherine Laaripuoh Omosule and George Boateng Kyei},
journal = {BMC Infectious Diseases},
year = {2026},
month = jul,
doi = {10.1186/s12879-026-14052-5},
url = {https://doi.org/10.1186/s12879-026-14052-5},
note = {CC BY},
}
RIS
TY - JOUR
TI - Infectious complications in kidney transplant recipients across Africa: a scoping review of epidemiology, microbiology, and prophylaxis strategies
AU - Sabastine Eugene Arthur
AU - AnneMarie Sankofi
AU - Michella Naa Awula Atswei Laryea
AU - Richeal Owusu
AU - James Odame Aboagye
AU - Catherine Laaripuoh Omosule
AU - George Boateng Kyei
PY - 2026
DA - 2026/07/01
JO - BMC Infectious Diseases
DO - 10.1186/s12879-026-14052-5
UR - https://doi.org/10.1186/s12879-026-14052-5
AB - Background Infectious complications remain the leading cause of morbidity and mortality in kidney transplant recipients (KTRs) across Africa, where immunosuppression is delivered amid endemic pathogens, resource constraints, and limited microbiological surveillance. These challenges are compounded by near-universal cytomegalovirus (CMV) seropositivity, high tuberculosis burden, and constrained access to standard prophylactic antivirals. Objectives To synthesize evidence on the epidemiology, microbiology, and management of infectious complications in African KTRs, with emphasis on context-adapted prophylaxis strategies and systemic gaps. Methods This scoping review searched PubMed and African Journals Online (2015–2025) for primary cohort studies, systematic reviews, and clinical trials published between 2015 and 2025 reporting infection outcomes in African KTRs, supplemented by global evidence on CMV prophylaxis in resource-limited settings. Foundational studies predating 2015 were included where no more recent equivalent existed. This review was conducted following the PRISMA Extension for Scoping Reviews (PRISMA-ScR). Studies were eligible if they reported infection outcomes in African kidney transplant recipients. Data were charted descriptively by infection type, country, and prophylaxis strategy. Results Bacterial urinary tract infections predominate early post-transplant, with Escherichia coli causing up to 54% of cases. CMV infection occurs in 13–63% of seropositive recipients despite prophylaxis, with rates varying by regimen and monitoring intensity; tissue-invasive disease is associated with acute rejection rates approaching 50%. Low-dose valacyclovir shows encouraging prophylactic efficacy comparable to valganciclovir at approximately one-sixth the cost, suggesting it may represent a pragmatic alternative in resource-limited African settings where valganciclovir is unavailable or unaffordable. Pediatric transplantation remains severely underdeveloped across sub-Saharan Africa, compounded by weight-based CMV dosing challenges and absent dedicated pediatric units. Critical systemic gaps, nephrology workforce deficits, and near-total absence of transplant infectious disease subspecialty training perpetuate high infectious morbidity after transplantation. Conclusions Improving outcomes will require evaluation of cost-effective prophylaxis protocols through prospective multicenter registries, alongside urgent investment in transplant infectious disease workforce capacity.
SN - 1471-2334
ER -